


Figure 5 (supplement). Phase III trial of surgery  $\pm$  postoperative adjuvant BCG immunotherapy versus best medical therapy as initial treatment for resectable stage IV melanoma (NIH Clinical Trials Identifier: NCT01013623).



\*, if at the time of surgery, patients are found to be unresectable, they should receive the best medical or radiation therapy for treatment of the residual disease.